Global hospitalization trends for Crohn's disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses / Fabián Juliao Baños    

Público ISBD Título : Global hospitalization trends for Crohn's disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses Tipo de documento : documento electrónico Autores : Fabián Juliao Baños, Fecha de publicación : 2022 Títulos uniformes : Clinical Gastroenterology and Hepatology Idioma : Inglés (eng) Palabras clave : Inflammatory Bowel Disease  Crohn’s Disease  Ulcerative Colitis  Hospitalization Rates  Epidemiology Resumen : Background & Aims: The evolving epidemiologic patterns of inflammatory bowel disease (IBD) throughout the world, in conjunction with advances in therapeutic treatments, may influence hospitalization rates of IBD. We performed a systematic review with temporal analysis of hospitalization rates for IBD across the world in the 21st century. Methods: We systematically reviewed Medline and Embase for population-based studies reporting hospitalization rates for IBD, Crohn’s disease (CD), or ulcerative colitis (UC) in the 21st century. Log-linear models were used to calculate the average annual percentage change (AAPC) with associated 95% confidence intervals (95% CIs). Random-effects meta-analysis pooled country-level AAPCs. Data were stratified by the epidemiologic stage of a region: compounding prevalence (stage 3) in North America, Western Europe, and Oceania vs acceleration of incidence (stage 2) in Asia, Eastern Europe, and Latin America vs emergence (stage 1) in developing countries. Results: Hospitalization rates for a primary diagnosis of IBD were stable in countries in stage 3 (AAPC, −0.13%; 95% CI, −0.72 to 0.97), CD (AAPC, 0.20%; 95% CI, −1.78 to 2.17), and UC (AAPC, 0.02%; 95% CI, −0.91 to 0.94). In contrast, hospitalization rates for a primary diagnosis were increasing in countries in stage 2 for IBD (AAPC, 4.44%; 95% CI, 2.75 to 6.14), CD (AAPC, 8.34%; 95% CI, 4.38 to 12.29), and UC (AAPC, 3.90; 95% CI, 1.29 to 6.52). No population-based studies were available for developing regions in stage 1 (emergence). Conclusions: Hospitalization rates for IBD are stabilizing in countries in stage 3, whereas newly industrialized countries in stage 2 have rapidly increasing hospitalization rates, contributing to an increasing burden on global health care systems. Mención de responsabilidad : Michael J. Buie, Joshua Quan, Joseph W. Windsor, Stephanie Coward, Tawnya M. Hansen, James A. King, Paulo G. Kotze, Richard B. Gearry, Siew C. Ng, Joyce W.Y. Mak, Maria T. Abreu, David T. Rubin, Charles N. Bernstein, Rupa Banerjee, Jesus K. Yamamoto-Furusho, Remo Panaccione, Cynthia H. Seow, Christopher Ma, Fox E. Underwood, Vineet Ahuja, Nicola Panaccione, Abdel-Aziz Shaheen, Jayna Holroyd-Leduc, Gilaad G. Kaplan, Domingo Balderramo, Vui Heng Chong, Fabián Juliao-Baños, Usha Dutta, Marcellus Simadibrata, Jamilya Kaibullayeva, Yang Sun, Ida Hilmi, Raja Affendi Raja Ali, Mukesh Sharma Paudel, Mansour Altuwaijri, Juanda Leo Hartono, Shu Chen Wei, Julajak Limsrivilai, Sara El Ouali, Beatriz Iade Vergara, Viet Hang Dao, Paul Kelly, Phoebe Hodges, Yinglei Miao y Maojuan Li Referencia : Clin Gastroenterol Hepatol. 2022 Jul 19;S1542-3565(22)00670-X. DOI (Digital Object Identifier) : 10.1016/j.cgh.2022.06.030 PMID : 35863682 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S154235652200670X Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6106 Global hospitalization trends for Crohn's disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses [documento electrónico] / Fabián Juliao Baños,  . - 2022. Obra : Clinical Gastroenterology and Hepatology Idioma : Inglés (eng) Palabras clave : Inflammatory Bowel Disease  Crohn’s Disease  Ulcerative Colitis  Hospitalization Rates  Epidemiology Resumen : Background & Aims: The evolving epidemiologic patterns of inflammatory bowel disease (IBD) throughout the world, in conjunction with advances in therapeutic treatments, may influence hospitalization rates of IBD. We performed a systematic review with temporal analysis of hospitalization rates for IBD across the world in the 21st century. Methods: We systematically reviewed Medline and Embase for population-based studies reporting hospitalization rates for IBD, Crohn’s disease (CD), or ulcerative colitis (UC) in the 21st century. Log-linear models were used to calculate the average annual percentage change (AAPC) with associated 95% confidence intervals (95% CIs). Random-effects meta-analysis pooled country-level AAPCs. Data were stratified by the epidemiologic stage of a region: compounding prevalence (stage 3) in North America, Western Europe, and Oceania vs acceleration of incidence (stage 2) in Asia, Eastern Europe, and Latin America vs emergence (stage 1) in developing countries. Results: Hospitalization rates for a primary diagnosis of IBD were stable in countries in stage 3 (AAPC, −0.13%; 95% CI, −0.72 to 0.97), CD (AAPC, 0.20%; 95% CI, −1.78 to 2.17), and UC (AAPC, 0.02%; 95% CI, −0.91 to 0.94). In contrast, hospitalization rates for a primary diagnosis were increasing in countries in stage 2 for IBD (AAPC, 4.44%; 95% CI, 2.75 to 6.14), CD (AAPC, 8.34%; 95% CI, 4.38 to 12.29), and UC (AAPC, 3.90; 95% CI, 1.29 to 6.52). No population-based studies were available for developing regions in stage 1 (emergence). Conclusions: Hospitalization rates for IBD are stabilizing in countries in stage 3, whereas newly industrialized countries in stage 2 have rapidly increasing hospitalization rates, contributing to an increasing burden on global health care systems. Mención de responsabilidad : Michael J. Buie, Joshua Quan, Joseph W. Windsor, Stephanie Coward, Tawnya M. Hansen, James A. King, Paulo G. Kotze, Richard B. Gearry, Siew C. Ng, Joyce W.Y. Mak, Maria T. Abreu, David T. Rubin, Charles N. Bernstein, Rupa Banerjee, Jesus K. Yamamoto-Furusho, Remo Panaccione, Cynthia H. Seow, Christopher Ma, Fox E. Underwood, Vineet Ahuja, Nicola Panaccione, Abdel-Aziz Shaheen, Jayna Holroyd-Leduc, Gilaad G. Kaplan, Domingo Balderramo, Vui Heng Chong, Fabián Juliao-Baños, Usha Dutta, Marcellus Simadibrata, Jamilya Kaibullayeva, Yang Sun, Ida Hilmi, Raja Affendi Raja Ali, Mukesh Sharma Paudel, Mansour Altuwaijri, Juanda Leo Hartono, Shu Chen Wei, Julajak Limsrivilai, Sara El Ouali, Beatriz Iade Vergara, Viet Hang Dao, Paul Kelly, Phoebe Hodges, Yinglei Miao y Maojuan Li Referencia : Clin Gastroenterol Hepatol. 2022 Jul 19;S1542-3565(22)00670-X. DOI (Digital Object Identifier) : 10.1016/j.cgh.2022.06.030 PMID : 35863682 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S154235652200670X Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6106

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001954	AC-2022-115	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

AC-2022-115 Adobe Acrobat PDF

Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: a Systematic Review / Fabián Juliao Baños    

Público ISBD Título : Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: a Systematic Review Tipo de documento : documento electrónico Autores : Fabián Juliao Baños, Fecha de publicación : 2020 Títulos uniformes : Clinical Gastroenterology and Hepatology Idioma : Inglés (eng) Palabras clave : Anti-TNF  ethnicity  incidence  inflammatory bowel disease  prevalence  race  risk factor Resumen : Background & Aims: The incidence of inflammatory bowel diseases (IBD) is increasing in Latin America. We performed a systematic review to identify clinical and epidemiologic features of IBD in Latin America (including Mexico, Central America, and South America) and the Caribbean. Methods: We searched MEDLINE, EMBASE, and SciELO databases for clinical or epidemiologic studies of Crohn’s disease (CD) or ulcerative colitis (UC) from Latin American and Caribbean countries and territories that reported incidence, prevalence, ratio of UC:CD, IBD phenotype, and treatment, through September 12, 2018. Data were extracted from 61 articles for analysis. Results: The incidence and prevalence of IBD have been steadily increasing in Latin America and the Caribbean. The incidence of CD in Brazil increased from 0.08 per 100,000 person-years in 1988 to 0.68 per 100,000 person-years in 1991–1995 to 5.5 per 100,000 person-years in 2015. The highest reported prevalence of IBD was in Argentina, in 2007, at 15 and 82 per 100,000 person-years for CD and UC, respectively. The ratio of UC:CD exceeded 1 in all regions throughout Latin America and the Caribbean with the exception of Brazil. Treatment with tumor necrosis factor antagonists increased steadily for patients with CD (43.4% of all patients in Brazil were treated in 2014) but less so for patients with UC (4.5% of all patients were treated in 2014). Surgery for IBD decreased with time. In Chile, surgeries were performed on 57.0% of patients with CD and 18.0% of patients with UC during the period of 1990–2002; these values decreased to 38.0% and 5.0%, respectively, during the period of 2012–2015. In Peru, 6.9% of patients with UC received colectomies in the period of 2001–2003 and 6.2% in 2004–2014. Conclusions: In a systematic review, we found the incidence of IBD to be increasing throughout Latin America and the Caribbean. Population-based epidemiology studies are needed to evaluate the increase in IBD in these regions, which differ from other global regions in climate, culture, demographics, diet, healthcare delivery and infrastructure, and socioeconomic status. Mención de responsabilidad : Paulo Gustavo Kotze, Fox E Underwood, Aderson Omar Mourão Cintra Damião, Jose Geraldo P Ferraz, Rogerio Saad-Hossne, Martin Toro, Beatriz Iade, Francisco Bosques-Padilla, Fábio Vieira Teixeira, Fabian Juliao-Banos, Daniela Simian, Subrata Ghosh, Remo Panaccione, Siew C Ng, Gilaad G Kaplan Referencia : Clin Gastroenterol Hepatol. 2020 Feb;18(2):304-312. DOI (Digital Object Identifier) : 10.1016/j.cgh.2019.06.030 PMID : 31252191 Derechos de uso : CC BY-NC-ND En línea : https://www.cghjournal.org/article/S1542-3565(19)30668-8/fulltext Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4244 Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: a Systematic Review [documento electrónico] / Fabián Juliao Baños,  . - 2020. Obra : Clinical Gastroenterology and Hepatology Idioma : Inglés (eng) Palabras clave : Anti-TNF  ethnicity  incidence  inflammatory bowel disease  prevalence  race  risk factor Resumen : Background & Aims: The incidence of inflammatory bowel diseases (IBD) is increasing in Latin America. We performed a systematic review to identify clinical and epidemiologic features of IBD in Latin America (including Mexico, Central America, and South America) and the Caribbean. Methods: We searched MEDLINE, EMBASE, and SciELO databases for clinical or epidemiologic studies of Crohn’s disease (CD) or ulcerative colitis (UC) from Latin American and Caribbean countries and territories that reported incidence, prevalence, ratio of UC:CD, IBD phenotype, and treatment, through September 12, 2018. Data were extracted from 61 articles for analysis. Results: The incidence and prevalence of IBD have been steadily increasing in Latin America and the Caribbean. The incidence of CD in Brazil increased from 0.08 per 100,000 person-years in 1988 to 0.68 per 100,000 person-years in 1991–1995 to 5.5 per 100,000 person-years in 2015. The highest reported prevalence of IBD was in Argentina, in 2007, at 15 and 82 per 100,000 person-years for CD and UC, respectively. The ratio of UC:CD exceeded 1 in all regions throughout Latin America and the Caribbean with the exception of Brazil. Treatment with tumor necrosis factor antagonists increased steadily for patients with CD (43.4% of all patients in Brazil were treated in 2014) but less so for patients with UC (4.5% of all patients were treated in 2014). Surgery for IBD decreased with time. In Chile, surgeries were performed on 57.0% of patients with CD and 18.0% of patients with UC during the period of 1990–2002; these values decreased to 38.0% and 5.0%, respectively, during the period of 2012–2015. In Peru, 6.9% of patients with UC received colectomies in the period of 2001–2003 and 6.2% in 2004–2014. Conclusions: In a systematic review, we found the incidence of IBD to be increasing throughout Latin America and the Caribbean. Population-based epidemiology studies are needed to evaluate the increase in IBD in these regions, which differ from other global regions in climate, culture, demographics, diet, healthcare delivery and infrastructure, and socioeconomic status. Mención de responsabilidad : Paulo Gustavo Kotze, Fox E Underwood, Aderson Omar Mourão Cintra Damião, Jose Geraldo P Ferraz, Rogerio Saad-Hossne, Martin Toro, Beatriz Iade, Francisco Bosques-Padilla, Fábio Vieira Teixeira, Fabian Juliao-Banos, Daniela Simian, Subrata Ghosh, Remo Panaccione, Siew C Ng, Gilaad G Kaplan Referencia : Clin Gastroenterol Hepatol. 2020 Feb;18(2):304-312. DOI (Digital Object Identifier) : 10.1016/j.cgh.2019.06.030 PMID : 31252191 Derechos de uso : CC BY-NC-ND En línea : https://www.cghjournal.org/article/S1542-3565(19)30668-8/fulltext Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4244

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001224	AC-2019-013	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

2019-013.pdf Adobe Acrobat PDF

---

1 (1 - 2 / 2) Por página: 25 50 100 200